G.N. Tech Venture

G.N. Tech Venture is a corporate investment firm established in 2000 as the venture capital arm of Kooksoondang Brewery Co. Ltd. The company primarily focuses on investing in technology companies, particularly in the electronic components sector, within South Korea. By supporting innovative ventures, G.N. Tech Venture aims to foster growth and development in the tech industry, leveraging its expertise and resources to enhance the success of its portfolio companies.

Chung-hee Hong

Chief Executive Officer

Junkyu Kang

Director

Sam-woo Lee

Director

9 past transactions

ONDA

Series B in 2021
T Port Inc. is an accommodation management platform. T Port Inc.'s real-time reservation management book can easily manage all bookings on the computer or smartphone anytime, anywhere.

ImmunoMet Therapeutics

Venture Round in 2021
ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products that are aimed to improve the quality of life of cancer patients. With more than 6 years of experience in the field of cancer metabolism and immunometabolism, ImmunoMet has developed a comprehensive pipeline of metabolic regulators preferentially targeting the cellular metabolism of drug-resistant cancer subpopulations and immuno-suppressors of anti-cancer effector T cells.

ExoCoBio

Series C in 2020
ExoCoBio Inc. is a South Korean company founded in 2017 that specializes in the development of biopharmaceuticals and cosmeceuticals utilizing stem cell-derived exosomes. These nano-vesicles play a crucial role in intercellular signaling, which is essential for skin and tissue regeneration. The company focuses on creating innovative therapeutics and cosmetic products aimed at enhancing cellular tissue regeneration, thereby promoting overall health and well-being. ExoCoBio's research and development efforts are geared toward providing effective alternatives for clinicians and improving the quality of life through advanced regenerative medicine solutions.

CARVI

Series B in 2020
CarVi, Inc. is a company based in San Jose, California, that specializes in advanced driver assistance systems (ADAS) and a contextual data platform designed to analyze driving behavior and habits. Founded in 2014, CarVi offers a unique combination of vision-based ADAS technology and a data platform that focuses on driver behaviors and 3D road data. The company's solutions aim to enhance safe driving by reducing accident risks while also monitoring various driving-related factors, including smoke detection, drunk driving detection, parking violations, and keyless entry systems. CarVi has established itself as an original equipment manufacturer (OEM) in the automotive sector and is now concentrating on telematics, a rapidly growing market projected to reach $100 billion by 2025. The data collected by CarVi, encompassing camera-based driving insights and environmental conditions, is integral to developing advanced features for self-driving vehicles.

Law&Company

Series B in 2019
Law&Company is representative legal tech company in Republic of Korea. The company provides a service called 'LawTalk(www.lawtalk.co.kr)', which is the largest online legal market place in Korea(5 times bigger then the 2nd player). Since 2016, the company invested on research about Artificial Intelligence especially on Text Mining and Machine Learning technology to analyze lawyers and client's activities in the service which helps to lawyers and clients find the right person based on their experience. Also, the company will launch document automation based service to generate legal documents starting from complaint and contract soon. The company has received more than 3 million dollars from 5 venture capital companies and many angel investors due to previous performance and upside potential in the Korean legal market.

Dr.Kitchen

Series B in 2017
Kitchen Doctor engages in research and development of diet programs for diabetes. Kitchen Doctor is based in Daejeon, South Korea with an additional office in Seoul, South Korea.

ImmunoMet Therapeutics

Series B in 2017
ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products that are aimed to improve the quality of life of cancer patients. With more than 6 years of experience in the field of cancer metabolism and immunometabolism, ImmunoMet has developed a comprehensive pipeline of metabolic regulators preferentially targeting the cellular metabolism of drug-resistant cancer subpopulations and immuno-suppressors of anti-cancer effector T cells.

Eutilex

Series A in 2016
Eutilex.Co.,Ltd. discovers and develops immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases. It develops anti-tumor T cell therapy and antibody therapeutics. The company was founded in 2015 and is based in Seoul, South Korea.